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In the past decade, numerous advances have taken place in the
understanding of pathogenesis and as a result, signiﬁcant pro-
gress has been made and is still being made in the development
of novel anti-inﬂammatory drugs (Bhandari et al., 2009).
Inﬂammation is a fundamental physiological process that is
essential for survival but at the same time is one of the major
causes of human morbidity and mortality (O’Neill, 2006;
Cheeseright et al., 2009). Therefore, investigation of new
anti-inﬂammatory agents is still a major challenge (Chao
et al., 2008; Stefan et al., 2008; Hynes et al., 2008). A few
COX-2 inhibitors have also been studied for the treatment of
cancer (Kalgutkar and Zhao, 2001) and Alzheimer’s disease
(Pasinetti, 1998).
Pyrazolone is an important pharmacophore which exhibits
widespread pharmacological properties, such as anticancer
(Brana et al., 2006), analgesic (Filho et al., 1998; Gokce
et al., 2009), anti-inﬂammatory (Ismail et al., 2007; El-Hawash
et al., 2006), antipyretic (El-Hawash et al., 2006; Souza et al.,
2002), antioxidant (Manojkumar et al., 2009), antiproliferative
(Kim et al., 2005), antimicrobial (Ragavan et al., 2009; Raman
et al., 2002, 2005; Bondock et al., 2008), activities. Edaravone
(Pal et al., 2008; Chegaev et al., 2009), (3-methyl-1-phenyl-2-
pyrazolin-5-one) is found as a promising drug for brain ische-
mia (Watanabe et al., 1994), myocardial ischemia (Kawai
et al., 1997), treatment of fatal neurodegenerative diseases
(Kimata et al., 2007) and cardiovascular diseases (Higashi
et al., 2006).
In the present study, we have demonstrated the ability of an
unusual class of synthetic molecules containing a pair of basic
moieties like pyrazolone and amino pyrimidine (5a–5j) as anti-
inﬂammatory, analgesic and antipyretic agents. Microwave
assisted synthesis for (5a–5j) and (6a–6j) were employed in sol-
vent-free conditions, the reaction time required was limited to
an average of less than 10 min. Pharmacological evaluation of
the molecules reveals that compounds 5a, 5c–5f, 5h exhibited
anti-inﬂammatory, analgesic and antipyretic efﬁcacy nearly
similar to the standard.2. Materials and methods
2.1. Chemistry
The title compounds were synthesized as per Scheme 1.
The starting materials, 3-methyl-1-substituted-1H-pyrazol-
5(4H)-ones (2a–2b), were obtained in high yields as per the
method reported (Pal et al., 2008; Kimata et al., 2007) by the
treatment of ethyl acetoacetate with 1-phenylhydrazine (1a)
or 1-(2,4-dinitrophenyl)hydrazine (1b) using a microwave oven.
The 4-acetyl-3-methyl-1-substituted-1H-pyrazol-5(4H)-ones
(3a–3b) were prepared by the acylation of (2a–2b) with the cor-
responding acid chloride following Jensen’s procedure (Jensen,
1959). The chalcone derivatives, 4-(3-(substituted)acryloyl)-3-
methyl-1-(substituted)-1H-pyrazol-5(4H)-ones, (4a–4j), wereprepared by reacting (3a–3b) with different substituted aro-
matic aldehydes by using 60% sodium hydroxide in ethanol.
4-(2-amino-6-(substituted)pyrimidin-4-yl)-3-methyl-1-(substi-
tuted)-1H-pyrazol-5(4H)-one (5a–5j) were prepared by reacting
(4a–4j) with guanidine hydrochloride. Finally (5a–5j) were re-
acted with substituted aromatic aldehydes to give correspond-
ing Schiff bases (6a–6j) in very good yields.
The synthesized compounds were assigned on the basis of
chromatographic, FT-IR, 1H NMR, Mass spectral data and
CHN analysis.
The FTIR spectra of the Schiff bases exhibited very similar
features and showed the expected bands for the characteristic
groups which are present in the compounds, such as CAH
and the C‚N stretching vibrations and another speciﬁc band
for ArACAN vibrations. Compounds (6a–6j) have C‚O
stretching bands in the range 1680–1655. The presence of only
one C‚O stretching band at 1640–1660 cm1 in (5a–5j) deriv-
atives as compared with (4a–4j) is an evidence of ring closure.
In the proton NMR spectral data, all protons were seen
according to the expected chemical shift and integral values.
The aromatic protons appeared as multiplet peaks within the
range 7.0–7.80 d ppm. Singlet signals derived from (ANH2)
and ArH of pyrimidine (5a–5j) structure appeared at 3.50–
3.70 and 8.10–8.15 d ppm, respectively. In case of (4a–4j),
two doublets in the range of 6.50–6.60 and 6.80–6.90 d ppm
are derived from ACH‚CH.
2.2. General
All the reactions were carried out with dry, freshly distilled sol-
vents under anhydrous conditions, unless otherwise noted.
Microwave irradiation was carried out using microwave oven
(KENSTAR Model No. OM-9928c, microwave 1200 W, input
range 230V-ac 50 Hz, microwave frequency 250 MHz). All the
products obtained were puriﬁed by column chromatography
using silica gel (100–200 mesh). Melting points were deter-
mined by open capillary on Thermonik precision apparatus
(Model-C-PMP-2, Mumbai, India) and are uncorrected. FT-
IR spectra of the powdered compounds were recorded on a
Tensor 27 spectrophotometer, Bruker optik (Germany) using
ATR method. 1H NMR spectra were recorded on a Bruker
spectrophotometer using TMS as an internal reference (chem-
ical shift represented in d ppm). Mass spectra were recorded on
GC–MS QP5050A System (benchtop quadrupole mass spec-
trophotometer). Elemental analysis was carried out in CHN
analyzer EA-1112, Thermo Finnigan. Purity of the compounds
was checked on TLC plates using silica gel G as the stationary
phase and was visualized using iodine chamber or under UV
chambers.
2.2.1. General procedure for preparation of 3-methyl-1-
(substituted)-1H-pyrazol-5(4H)-one (2a–2b)
The 3-methyl-1-(substituted)-1H-pyrazol-5(4H)-one deriva-
tives were prepared as per the reported method and puriﬁed
by recrystallization from ethanol (Pal et al., 2008; Kimata
et al., 2007).
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6d -H -2-OH -4-CH3
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6i -(2,4-NO2) -2-NO2 -4-Cl
6j -(2,4-NO2) -4 -4-CH3
Scheme 1 Synthesis of (6a–6e) using phenylhydrazine (1a) and 1-(2,4-dinitrophenyl)hydrazine (2b).
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236 R.V. Antre et al.2.2.1.1. 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one (2a). mp
117–121 C; yield 82% (Mohanty et al., 1977).
2.2.1.2. 3-Methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one
(2b).mp 68–72 C; yield 86%; FTIR (ATR) cm1: 3356 (NH),
2903 (CH3 stretch), 1730, (C‚O ketone), 1536, 1232 (NO2),
1367 (CH3 bend), 1314 (CAN); mass: m/z 264 (M
+), 265
(M+ 1, 12.7%); 266 (M+ 2, 1.1); 1H NMR (400 MHz,
CDCl3, d ppm), 2.22 (s, 3H, CH3), 7.65 (d, 2H, ArH), 7.80
(s, 2H, ArH), 7.95 (s, 1H, NH).
2.2.2. General procedure for preparation of 4-acetyl-3-methyl-1-
substituted-pyrazol-5(4H)-one (3a–3b)
The 4-acetyl-3-methyl-1-(substituted)-pyrazol-5(4H)-one deriv-
atives were prepared as per the Jensen procedure (Jensen, 1959).
2.2.2.1. 4-Acetyl-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
(3a). mp 61 C; yield 68% (Mohanty et al., 1977)
2.2.2.2. 4-Acetyl-3-methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-
5(4H)-one (3b). mp 85–88 C; yield 82%; FTIR (ATR) cm1:
3350 (NH), 2901 (CH3 stretch), 1734, 1665 (C‚O ketone),
1536, 1232 (NO2), 1367 (CH3 bend), 1318 (CAN); mass:
m/z 306 (M+), 307 (M+ 1, 14.4%); 308 (M+ 2, 1.3); 1H
NMR (400 MHz, CDCl3, d ppm), 2.05 (s, 3H, CH3), 2.30 (s,
3H, CH3), 7.70 (d, 1H, ArH), 7.80 (s, 1H, ArH), 7.90 (s, 1H,
NH).
2.2.3. General procedure for the preparation of 4-((E)-3-
(substituted)acryloyl)-3-methyl-1-(substituted)-1H-pyrazol-
5(4H)-one as chalcone derivatives (4a–4j)
Substituted aromatic aldehydes (0.001 mol), 4-acetyl-3-methyl-
1-(substituted)-pyrazol-5(4H)-one (0.001 mol) and 95% etha-
nol (20 mL) were mix in a round bottom ﬂask, 10 mL of
60% aqueous sodium hydroxide solution added drop wise.
Resulting mixture was stirred for 2 h at 5–10 C, poured onto
crushed ice and acidiﬁed with dilute HCl. The precipitate ob-
tained was ﬁltered and washed twice with cold water. The
resulting solid was allowed to air dry and recrystallized from
ethanol.
2.2.3.1. (4E)-4-[3-(4-hydroxy-3-methoxyphenyl)-2-propeno-
nyl]-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (4a). mp
165 C; yield 72%; FTIR (ATR) cm1: 3528 (phenolic OH),
3359 (NH), 2883 (CH3 stretch), 1724, 1686 (C‚O ketone),
1497 (C‚C Aliphatic), 1373 (CH3 bend), 1297 (CAN), 1242
(CAO); mass: m/z 350 (M+), 351 (M+ 1, 21%), 352
(M+ 2, 3.7%); 1H NMR (400 MHz, DMSO-d6, d ppm),
2.50 (s, 3H, CH3), 3.50 (s, 3H, OCH3), 4.50 (s, 1H, OH),
6.50 (d, 1H, ACH‚), 6.85 (d, 1H, ‚CHAAr), 7.10–7.15 (m,
5H, ArH), 7.40–7.35 (m, 3H, ArH), 7.90 (s, 1H, NH). Anal.
Calcd. (%) for C20H18N2O4: C, 68.56; H, 5.18; N, 8.00. Found:
C, 68.45; H, 5.12; N, 8.11.
2.2.3.2. (4E)-4-[3-(4-nitrophenyl)-2-propenonyl]-3-methyl-1-
phenyl-1H-pyrazol-5(4H)-one (4b). mp 128 C; yield 77%
(Mohanty et al., 1977).
2.2.3.3. (4E)-4-[3-(4-methoxyphenyl)-2-propenonyl]-3-methyl-
1-phenyl-1H-pyrazol-5(4H)-one (4c). mp 151 C; yield 65%
(Mohanty et al., 1977).2.2.3.4. (4E)-4-[3-(2-hydroxyphenyl)-2-propenonyl]-3-methyl-
1-phenyl-1H-pyrazol-5(4H)-one (4d). mp 169 C; yield 61%;
FTIR (ATR) cm1: 3420 (phenolic OH), 3361 (NH), 3369
(NH), 2943 (CH3 stretch), 1727 1689 (C‚O ketone), 1489
(C‚C aliphatic), 1366 (CH3 bend), 1277 (CAN); mass: m/z
320 (M+), 321 (M+ 1, 20.9%), 322 (M+ 2, 2.4%); 1H
NMR (400 MHz, CDCl3, d ppm), 2.20 (s, 3H, CH3), 4.90 (s,
1H, OH), 6.60 (d, 1H, ACH‚), 6.90 (d, 1H, ‚CHAAr),
7.10–7.20 (m, 5H, ArH), 7.30 (q, 2H, ArH), 7.65 (t, 2H,
ArH), 7.90 (s, 1H, NH). Anal. Calcd. (%) for C19H16N2O3:
C, 71.24; H, 5.03; N, 8.74. Found: C, 71.29; H, 5.17; N,
8.58.
2.2.3.5. (4E)-4-[3-(4-dimethylamiophenyl)-2-propenonyl]-3-
methyl-1-phenyl-1H-pyrazol-5(4H)-one (4e). mp 210 C; yield
80% (Mohanty et al., 1977).
2.2.3.6. (4E)-4-[3-(4-hydroxy-3-methoxyphenyl)-2-propeno-
nyl]-3-methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one
(4f). mp 123 C; yield 79%; FTIR (ATR) cm1: 3341 (OH),
3370 (NH), 2903 (CH3 stretch), 1730, 1663 (C‚O ketone),
1442 (C‚C Aliphatic), 1536, 1232 (NO2), 1367 (CH3 bend),
1314 (CAN), 1161 (CAO); mass: m/z 440 (M+), 441
(M+ 1, 22%), 442 (M+ 2, 4.1%); 1H NMR (400 MHz,
CDCl3, d ppm), 2.20 (s, 3H, CH3), 3.50 (s, 3H, OCH3), 4.50
(s, 1H, OH), 6.50 (d, 1H, ACH‚), 6.90 (d, 1H, ‚CHAAr),
7.10 (d, 2H, ArH), 7.20 (s, 1H, ArH), 7.45 (d, 2H, ArH),
7.50(s, 1H, ArH), 7.95 (s, 1H, NH). Anal. Calcd. (%) for
C20H16N4O8: C, 54.55; H, 3.66; N, 12.72. Found: C, 54.45;
H, 3.79; N, 12.78.
2.2.3.7. (4E)-4-[3-(3-nitrophenyl)-2-propenonyl]-3-methyl-1-
(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (4g). mp 186 C;
yield 72%; FTIR (ATR) cm1: 3371 (NH), 2978 (CH3 stretch),
1724, 1690 (C‚O ketone), 1618 (C‚C Ar), 1442 (C‚C ali-
phatic), 1512, 1243 (NO2), 1382 (CH3 bend), 1326 (CAN);
mass: m/z 439 (M+), 440 (M+ 1, 21.0%), 435 (M+ 2,
4.1%); 1H NMR (400 MHz, CDCl3, d ppm), 2.20 (s, 3H,
CH3), 6.65 (d, 1H, ACH‚), 6.85 (d, 1H, ‚CHAAr), 7.05
(d, 2H, ArH), 7.15 (s, 1H, ArH), 7.45–7.50 (m, 4H, ArH),
7.90 (s, 1H, NH). Anal. Calcd. (%) for C19H13N5O8: C,
51.94; H, 2.98; N, 15.94. Found: C, 51.58; H, 2.57; N,
15.32.
2.2.3.8. (4E)-4-[3-(4-dimethylaminophenyl)-2-propenonyl]-3-
methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (4h). mp
180 C; yield 81%; FTIR (ATR) cm1: 3365 (NH), 2902
(CH3 stretch), 1720, 1660 (C‚O ketone), 1485 (C‚C ali-
phatic), 1534, 1232 (NO2), 1371 (CH3 bend), 1336 (CAN);
mass: m/z 437 (M+), 438 (M+ 1, 23.1%), 439 (M+ 2,
3.8%), 1H NMR (400 MHz, CDCl3, d ppm), 2.20 (s, 3H,
CH3), 2.65 (s, 6H, AN‚(CH3)2), 6.55 (d, 1H, ACH‚), 6.85
(d, 1H, ‚CHAAr), 7.10–7.20 (m, 4H, ArH), 7.65 (d, 2H,
ArH), 7.70 (s, 1H, ArH), 7.90 (s, 1H, NH). Anal. Calcd. (%)
for C21H19N5O6: C, 57.66; H, 4.38; N, 16.01. Found: C,
57.16; H, 4.23; N, 16.15.
2.2.3.9. (4E)-4-[3-(2-nitrophenyl)-2-propenonyl]-3-methyl-1-
(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (4i). mp 162 C;
yield 72%; FTIR (ATR) cm1: 3352 (NH), 2916 (CH3 stretch),
1729, 1699 (C‚O ketone), 1424 (C‚C aliphatic), 1518, 1332
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+),
440 (M+ 1, 21%), 441 (M+ 2, 4.0%); 1H NMR
(400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 6.55 (d,
1H, ACH‚), 6.85 (d, 1H, ‚CHAAr), 7.30–7.40 (m, 4H,
ArH), 7.55 (d, 2H, ArH), 7.75 (s, 1H, ArH), 7.90 (s, 1H,
NH). Anal. Calcd. (%) for C19H13N5O8: C, 51.94; H, 2.98;
N, 15.94. Found: C, 51.13; H, 2.17; N, 15.11.
2.2.3.10. (4E)-4-[3-(4-chlorophenyl)-2-propenonyl]-3-methyl-
1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (4j). mp 110 C;
yield 83%; FTIR (ATR) cm1: 3345 (NH), 2995 (CH3 stretch),
1700, 1658 (C‚O ketone), 1488 (C‚C aliphatic), 1518, 1329
(NO2), 1225 (CAN); mass: m/z 428 (M
+), 429 (M+ 1,
20.1%), 430 (M+ 2, 31.7%); 1H NMR (400 MHz, DMSO-
d6, d ppm), 2.20 (s, 3H, CH3), 6.55 (d, 1H, ACH‚), 6.80 (d,
1H, ‚CHAAr), 7.35–7.40 (m, 4H, ArH), 7.65 (d, 2H, ArH),
7.70 (s, 1H, ArH), 7.90 (s, 1H, NH). Anal. Calcd. (%) for
C19H13ClN4O6: C, 53.22; H, 3.06; N, 13.07. Found: C, 53.11;
H, 3.17; N, 13.11.
2.2.4. General procedure for the preparation of 4-(2-amino-6-
(substituted)pyrimidin-4-yl)-3-methyl-1-(substituted)-1H-
pyrazol-5(4H)-one (5a–5j)
2.2.4.1. Conventional procedure. Mixture of appropriate chal-
cone derivatives (4a–4j) (0.001 mol) and guanidine hydrochlo-
ride (0.002 mol) was added in absolute ethanol (20 mL),
K2CO3 (4.0 g) and mixture was reﬂuxed on water bath for
16-18 h. Reaction completion examined by TLC, the solvent
was completely evaporated and residue was poured into ice
cold water. The solid product was dried and recrystallized
from ethanol.
2.2.4.2. Microwave irradiation. Mixture of the chalcone deriv-
atives (4a–4j) (0.001 mol) and guanidine hydrochloride
(0.002 mol) was added in acetone (5 mL) and ethanol (5
mL), K2CO3 and stirred vigorously. After 5 min, solvent was
evaporated and the dry powder was irradiated in microwave
oven for the appropriate time in between 6–9 min at 50%
power output. Reaction completion examined by TLC, after
completion of reaction chilled water was added to the reaction
mixture. The solid product was ﬁltered, dried and recrystal-
lized from ethanol.
2.2.4.2.1. 4-(2-Amino-6-(3-methoxy-4-hydroxyphenyl)pyr-
imidin-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (5a).
mp 185 C; yield 70%; FTIR (ATR) cm1: 3371, 3396
(NH2), 2918 (CH3 stretch), 1654 (C‚O ketone), 1313 (CH3
bend), 1286 (CAN); mass: m/z 389 (M+), 390 (M+ 1,
24.5%), 391 (M+ 2, 2.1%); 1H NMR (400 MHz, DMSO-
d6, d ppm), 2.30 (s, 3H, CH3), 3.60 (s, 2H, NH2), 3.70 (s,
3H, OCH3), 4.60 (s, 1H, OH), 7.10–7.20 (m, 5H, ArH), 7.40
(d, 2H, ArH), 7.70 (s, 1H, ArH), 7.95 (s, 1H, NH), 8.10(s,
1H, ArH). Anal. Calcd. (%) for C21H19N5O3: C, 64.77; H,
4.92; N, 17.98. Found: C, 64.18; H, 4.65; N, 17.89.
2.2.4.2.2. 4-(2-Amino-6-(4-nitro)pyrimidin-4-yl)-3-methyl-
1-phenyl-1H-pyrazol-5(4H)-one (5b). mp 280 C; yield 84%;
FTIR (ATR) cm1: 3338, 3256 (NH2), 2916 (CH3 stretch),
1658 (C‚O ketone), 1329 (CH3 bend), 1160 (CAN); mass:
m/z 388 (M+), 389 (M+ 1, 24.1%), 390 (M+ 2, 2.4%); 1H
NMR (400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 3.50
(s, 2H, NH2), 7.15–7.20 (m, 5H, ArH), 7.30–7.45 (m, 4H,
ArH), 7.90 (s, 1H, NH), 8.10 (s, 1H, ArH). Anal. Calcd. (%)for C20H16N6O3: C, 61.85; H, 4.15; N, 21.64. Found: C,
61.98; H, 4.11; N, 21.55.
2.2.4.2.3. 4-(2-Amino-6-(4-methoxyphenyl)pyrimidin-4-yl)-
3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (5c). mp 173 C;
yield 79%; FTIR (ATR) cm1: 3283, 3328 (NH2), 1654
(C‚O ketone), 1331 (CH3 bend), 1132 (CAN); mass: m/z
373 (M+), 374 (M+ 1, 23%), 375 (M+ 2, 2.9%); 1H NMR
(400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 2.80 (s,
1H, OCH3), 3.50 (s, 2H, NH2), 7.00–7.10 (m, 5H, ArH),
7.40–7.45 (m, 4H, ArH), 7.95 (s, 1H, NH), 8.10 (s, 1H,
ArH). Anal. Calcd. (%) for C21H19N5O2: C, 67.55; H, 5.13;
N, 18.76. Found: C, 67.56; H, 5.34; N, 18.78.
2.2.4.2.4. 4-(2-Amino-6-(4-hydroxyphenyl)pyrimidin-4-yl)-
3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (5d). mp 161 C;
yield 76%; FTIR (ATR) cm1: 3461 (OH), 3388, 3316
(NH2), 2946 (CH3 stretch), 1644 (C‚O ketone), 1265
(CAN); mass: m/z 359 (M+), 360 (M+ 1, 2.5%), 361
(M+ 2, 3.1%); 1H NMR (400 MHz, CDCl3, d ppm), 2.20
(s, 3H, CH3), 3.60 (s, 2H, NH2), 4.90 (s, 1H, OH), 7.10–7.20
(m, 5H, ArH), 7.45 (t, 2H, ArH), 7.55 (d, 2H, ArH), 7.95 (s,
1H, NH), 8.15 (s, 1H, ArH). Anal. Calcd. (%) for
C20H17N5O2: C, 66.84; H, 4.77; N, 19.49. Found: C, 66.66;
H, 4.67; N, 19.33.
2.2.4.2.5. 4-(2-Amino-6-(4-(dimethylamino)phenyl)pyrimi-
din-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (5e). mp
182 C; yield 86%; FTIR (ATR) cm1: 3420, 3371 (NH2),
2918 (CH3 stretch), 1654 (C‚O ketone), 1618 (C‚C Ar),
1313 (CH3 bend), 1286 (CAN); mass: m/z 386 (M
+), 387
(M+ 1, 24.0%), 388 (M+ 2, 3.4%); 1H NMR (400 MHz,
CDCl3, d ppm), 2.20 (s, 3H, CH3), 2.80 (s, 6H, AN‚(CH3)2),
3.50 (s, 2H, NH2), 7.15–7.20 (m, 5H, ArH), 7.30–7.45 (m, 4H,
ArH), 7.90 (s, 1H, NH), 8.10 (s, 1H, ArH). Anal. Calcd. (%)
for C22H22N6O: C, 68.38; H, 5.74; N, 21.75. Found: C,
68.14; H, 5.87; N, 21.81.
2.2.4.2.6. 4-(2-Amino-6-(3-methoxy-4-hydroxyphenyl)pyr-
imidin-4-yl)-3-methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-
5(4H)-one (5f). mp 93 C; yield 70%; FTIR (ATR) cm1:
3689 (OH), 3420, 3371 (NH2), 2918 (CH3 stretch), 1654
(C‚O ketone), 1335 (CH3 bend), 1517, 1286 (NO2); mass:
m/z 479 (M+), 480 (M+ 1, 25.5%), 481 (M+ 2, 2.7%); 1H
NMR (400 MHz, CDCl3, d ppm), 2.30 (s, 3H, CH3), 3.70 (s,
2H, NH2), 3.75 (s, 3H, OCH3), 4.60 (s, 1H, OH), 7.10–7.20
(m, 3H, ArH), 7.40 (d, 2H, ArH), 7.70 (s, 1H, ArH), 7.90 (s,
1H, NH), 8.05(s, 1H, ArH). Anal. Calcd. (%) for
C21H17N7O7: C, 52.61; H, 3.57; N, 20.45. Found: C, 52.71;
H, 3.78; N, 20.36.
2.2.4.2.7. 4-(2-Amino-6-(3-nitro)pyrimidin-4-yl)-3-methyl-
1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (5g). mp 210 C;
yield 78%; FTIR (ATR) cm1: 3390, 3287 (NH2), 2946 (CH3
stretch), 1648 (C‚O ketone), 1334 (CH3 bend), 1518, 1312
(NO2), 1137 (CAN); mass: m/z 478 (M
+), 479 (M+ 1,
25.0%), 480 (M+ 2, 2.3%); 1H NMR (400 MHz, CDCl3, d
ppm), 2.20 (s, 3H, CH3), 3.50 (s, 2H, NH2), 7.15–7.20 (m,
3H, ArH), 7.35–7.45 (m, 4H, ArH), 7.95 (s, 1H, NH), 8.15
(s, 1H, ArH). Anal. Calcd. (%) for C20H14N8O7: C, 50.21;
H, 2.95; N, 23.42. Found: C, 50.13; H, 2.78; N, 23.28.
2.2.4.2.8. 4-(2-Amino-6-(4-(dimethylamino)-phenyl)-pyrim-
idin-4-yl)-3-methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-
one (5h). mp 152 C; yield 75%; FTIR (ATR) cm1: 3371,
3420 (NH2), 2918 (CH3 stretch), 1654 (C‚O ketone), 1313
(CH3 bend), 1588, 1286 (NO2), 1139 (CAN); mass: m/z 476
238 R.V. Antre et al.(M+), 477 (M+ 1, 24.1%), 478 (M+ 2, 4.3%) 1H NMR
(400 MHz, CDCl3, d ppm), 2.20 (s, 3H, CH3), 2.85 (s, 6H,
AN‚(CH3)2), 3.65 (s, 2H, NH2), 7.15–7.20 (m, 3H, ArH),
7.30–7.45 (m, 4H, ArH), 7.90 (s, 1H, NH), 8.10 (s, 1H,
ArH). Anal. Calcd. (%) for C22H20N8O5: C, 55.46; H, 4.23;
N, 23.52. Found: C, 55.31; H, 4.12; N, 23.65.
2.2.4.2.9. 4-(2-Amino-6-(2-nitrophenyl)-pyrimidin-4-yl)-3-
methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (5i). mp
172 C; yield 68%; FTIR (ATR) cm1: 3374, 3366 (NH2),
2946 (CH3 stretch), 1648 (C‚O ketone), 1334 (CH3 bend),
1518, 1312 (NO2), 1132 (CAN); mass: m/z 478 (M
+), 479
(M+ 1, 24.8%), 480 (M+ 2, 2.2%); 1H NMR (400 MHz,
DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 3.50 (s, 2H, NH2),
7.15–7.20 (m, 5H, ArH), 7.45 (d, 2H, ArH), 7.55 (s, 1H,
ArH), 7.90 (s, 1H, NH), 8.10 (s, 1H, ArH). Anal. Calcd. (%)
for C20H14N8O7: C, 50.21; H, 2.95; N, 23.42. Found: C,
50.29; H, 2.78; N, 23.10.
2.2.4.2.10. 4-(2-Amino-6-(4-chlorophenyl)-pyrimidin-4-yl)-
3-methyl-1-(2,4-dinitrophenyl)-1H-pyrazol-5(4H)-one (5j).
mp 123 C; yield 82%; FTIR (ATR) cm1: 3426, 3386
(NH2), 2953 (CH3 stretch), 1660 (C‚O ketone), 1330 (CH3
bend), 1506, 1316 (NO2), 1133(CAN); mass: m/z 467 (M
+),
468 (M+ 1, 21.8%), 469 (M+ 2, 32.7%); 1H NMR
(400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 3.50 (s,
2H, NH2), 7.45–7.50 (m, 4H, ArH), 7.55 (d, 2H, ArH), 7.65
(s, 1H, ArH), 7.90 (s, 1H, NH), 8.15 (s, 1H, ArH). Anal. Calcd.
(%) for C20H14ClN7O5: C, 51.35; H, 3.02; N, 20.96. Found: C,
51.34; H, 3.18; N, 20.78.
2.2.5. General procedure for the preparation of 4-(2-
(substituted)-6- (substituted)pyrimidin-4-yl)-3-methyl-1-
phenyl-1H-pyrazol-5(4H)-one as Schiff bases (6a–6j)
2.2.5.1. Conventional procedure. To a mixture of 4-(2-amino-6-
(substituted)pyrimidin-4-yl)-3-methyl-1-(substituted)-1H-pyra-
zol-5(4H)-one (5a–5j) (0.001 mol) and substituted aromatic
aldehydes (0.001 mol) dissolved in ethanol (15 mL), 2–4 drops
of glacial acetic acid were added and mixture was reﬂuxed in
water bath for 10–12 h. Reaction completion was examined
by TLC, the solvent was completely evaporated and residue
was poured into ice cold water. The solid product was dried
and crystallized from ethanol.
2.2.5.2. Microwave irradiation. Mixture of 4-(2-amino-6-
(substituted)pyrimidin-4-yl)-3-methyl-1-(substituted)-1H-pyra-
zol-5(4H)-one (5a–5j) (0.001 mol) and substituted aromatic
aldehydes (0.001 mol) dissolved in ethanol (15 mL), 2–4 drops
of glacial acetic acid added with stirring. After 5 min, the sol-
vent was evaporated and dry powder was irradiated in a micro-
wave oven for the appropriate time in between 5–7 min at 30%
power output. Reaction completion examined by TLC, after
completion of reaction chilled water was added to the reaction
mixture. The solid product was dried and crystallized from
ethanol.
2.2.5.2.1. 4-(2-(4-Nitrobenzylidenamino)-6-(4-hydroxy-3-
methoxyphenyl)pyrimidin-4-yl)-3-methyl-1-phenyl-1H-pyrazol-
5(4H)-one (6a). mp 215 C; yield 84%; FTIR (ATR) cm1:
3501 (phenolic OH), 3356 (NH), 2905 (CH3 stretch), 1659
(C‚O ketone), 1367 (CH3 bend), 1231 (CAN); mass: m/z
522 (M+), 523 (M+ 1, 30.6%), 524 (M+ 2, 6.1%); 1H
NMR (400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 3.70
(s, 3H, OCH3), 4.60 (s, 1H, OH), 7.05–7.10 (m, 5H, ArH),7.35–7.40 (m, 4H, ArH), 7.70 (s, 1H, ArH), 7.80 (d, 2H
ArH), 7.95 (s, 1H, NH), 8.15(s, 1H, ArH) 8.30 (s, 1H,
ACH‚NA). Anal. Calcd. (%) for C28H22N6O5: C, 64.36; H,
4.24; N, 16.08. Found: C, 64.17; H, 4.27; N, 16.41.
2.2.5.2.2. 4-(2-(4-Methylbenzylidenamino)-6-(4-nitro)pyr-
imidin-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (6b).
mp 153 C; yield 62%; FTIR (ATR) cm1: 3351 (NH), 2905
(CH3 stretch), 1660 (C‚O ketone), 1367 (CH3 bend), 1231
(CAN); mass: m/z 490 (M+), 491 (M+ 1, 30.7%), 492
(M+ 2, 5.7%); 1H NMR (400 MHz, DMSO-d6, d ppm),
2.20 (s, 3H, CH3), 2.35 (s, 3H, CH3), 7.15–7.20 (m, 5H,
ArH), 7.30–7.40 (m, 4H, ArH), 7.60–7.65 (m, 4H, ArH), 7.90
(s, 1H, NH), 8.10 (s, 1H, ArH), 8.25 (s, 1H,ACH‚NA). Anal.
Calcd. (%) for C28H22N6O3: C, 68.56; H, 4.52; N, 17.13.
Found: C, 68.71; H, 4.57; N, 17.10.
2.2.5.2.3. 4-(2-(4-Nitrobenzylidenamino)-6-(4-methoxy-
phenyl)pyrimidin-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-
one (6c). mp 188 C; yield 78%; FTIR (ATR) cm1: 3359
(NH), 2909 (CH3 stretch), 1660 (C‚O ketone), 1371 (CH3
bend), 1313 (CAO), 1232 (CAN); mass: m/z 506 (M+), 507
(M+ 1, 32.1%), 508 (M+ 2, 4.7%); 1H NMR (400 MHz,
DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 2.80 (s, 1H, OCH3),
7.00–7.10 (m, 5H, ArH), 7.40–7.45 (m, 4H, ArH), 7.55–7.60
(m, 4H, ArH), 7.90 (s, 1H, NH), 8.15 (s, 1H, ArH), 8.25 (s,
1H, ACH‚NA). Anal. Calcd. (%) for C28H22N6O4: C,
66.40; H, 4.38; N, 16.59. Found: C, 66.27; H, 4.43; N,
16.91.
2.2.5.2.4. 4-(2-(4-Methylbenzylidenamino)-6-(2-hydroxy-
phenyl)pyrimidin-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-
one (6d). mp 183 C; yield 80%; FTIR (ATR) cm1: 3525
(OH), 3354 (NH), 2896 (CH3 stretch), 1657 (C‚O ketone),
1367 (CH3 bend), 1286 (CAN); mass: m/z 461 (M
+), 462
(M+ 1, 30.6%), 463 (M+ 2, 5.6%); 1H NMR (400 MHz,
CDCl3, d ppm), 2.20 (s, 3H, CH3), 2.35 (s, 3H, CH3), 4.90
(s, 1H, OH), 7.10–7.20 (m, 5H, ArH), 7.45–7.50 (m, 4H,
ArH), 7.55 (d, 2H, ArH), 7.60 (t, 2H, ArH), 7.90 (s, 1H,
NH), 8.15 (s, 1H, ArH), 8.25 (s, 1H,ACH‚NA). Anal. Calcd.
(%) for C28H23N5O2: C, 72.87; H, 5.02; N, 15.17. Found: C,
72.92; H, 5.09; N, 15.45.
2.2.5.2.5. 4-(2-(4-Nitrobenzylidenamino)-6-(4-(dimethyl-
amino)phenyl)pyrimidin-4-yl)-3-methyl-1-phenyl-1H-pyrazol-
5(4H)-one (6e). mp 185 C; yield 83%; FTIR (ATR) cm1:
3363 (NH), 2918 (CH3 stretch), 1658 (C‚O), 1367 (CH3
bend); mass: m/z 519 (M+), 520 (M+ 1, 31.7%), 521
(M+ 2, 5.4%); 1H NMR (400 MHz, CDCl3, d ppm), 2.20
(s, 3H, CH3), 2.80 (s, 6H, AN‚(CH3)2), 7.10–7.20 (m, 5H,
ArH), 7.45–7.50 (m, 4H, ArH), 7.50 (d, 2H, ArH), 7.60 (d,
2H, ArH), 7.90 (s, 1H, NH), 8.15 (s, 1H, ArH), 8.25 (s, 1H,
ACH‚NA). Anal. Calcd. (%) for C29H25N7O3: C, 67.04; H,
4.85; N, 18.87. Found: C, 67.34; H, 4.98; N, 18.56.
2.2.5.2.6. 4-(2-(4-Chlorobenzylidenamino)-6-(4-hydroxy-3-
methoxyphenyl)pyrimidin-4-yl)-3-methyl-1-(2,4-dinitrophenyl-
phenyl)-1H-pyrazol-5(4H)-one (6f). mp 195 C; yield 87%;
FTIR (ATR) cm1: 3501 (OH), 3369 (NH), 2905 (CH3
stretch), 1659 (C‚O ketone), 1367 (CH3 bend), 1528, 1231
(NO2); mass: m/z 601 (M
+), 602 (M+ 1, 32.3%), 603
(M+ 2, 32.5%); 1H NMR (400 MHz, CDCl3, d ppm), 2.20
(s, 3H, CH3), 3.75 (s, 3H, OCH3), 4.80 (s, 1H, OH), 7.05–
7.10 (m, 4H, ArH), 7.35 (s, 1H, ArH), 7.40 (d, 2H, ArH),
7.70 (s, 1H, ArH), 7.80 (d, 2H ArH), 7.95 (s, 1H, NH),
8.10(s, 1H, ArH), 8.30 (s, 1H, ACH‚NA). Anal. Calcd.
Microwave assisted synthesis of novel pyrazolone derivatives attached to a pyrimidine moiety 239(%) for C28H20ClN7O7: C, 55.87; H, 3.35; N, 16.29. Found: C,
55.78; H, 3.22; N, 16.45.
2.2.5.2.7. 4-(2-(4-Chlorobenzylidenamino)-6-(3-nitro)pyr-
imidin-4-yl)-3-methyl-1-(2,4-dinitrophenylphenyl)-1H-pyrazol-
5(4H)-one (6g). mp 198 C; yield 77%; FTIR (ATR) cm1:
3351 (NH), 2915 (CH3 stretch), 1680 (C‚O ketone), 1368
(CH3 bend), 1529, 1337 (NO2); mass: m/z 600 (M
+), 601
(M+ 1, 32.2%), 602 (M+ 2, 32.8%); 1H NMR (400 MHz,
CDCl3, d ppm), 2.20 (s, 3H, CH3), 7.15–7.20 (m, 4H, ArH),
7.30–7.40 (m, 4H, ArH), 7.55 (s, 1H, ArH), 7.60 (d, 2H,
ArH), 7.95 (s, 1H, NH), 8.10 (s, 1H, ArH), 8.25 (s, 1H,
ACH‚NA). Anal. Calcd. (%) for C27H17ClN8O7: C, 53.96;
H, 2.85; N, 18.65. Found: C, 53.77; H, 2.78; N, 18.55.
2.2.5.2.8. 4-(2-(4-Chlorobenzylidenamino)-6-(4-(dimethyl-
amino)phenyl)pyrimidin-4-yl)-3-methyl-1-(2,4-dinitrophenyl-
phenyl)-1H-pyrazol-5(4H)-one (6h). mp 192 C; yield 81%;
FTIR (ATR) cm1: 3358 (NH), 2915 (CH3 stretch), 1655
(C‚O ketone), 1369 (CH3 bend), 1527, 1314 (NO2), 1231
(CAN); mass: m/z 598 (M+), 599 (M+ 1, 34.8%), 600
(M+ 2, 38.4%); 1H NMR (400 MHz, CDCl3, d ppm), 2.20
(s, 3H, CH3), 2.80 (s, 6H, AN‚(CH3)2), 7.10–7.20 (m, 4H,
ArH), 7.45–7.50 (m, 4H, ArH), 7.50 (d, 2H, ArH), 7.65 (s,
1H, ArH), 7.90 (s, 1H, NH), 8.10 (s, 1H, ArH), 8.30 (s, 1H,
ACH‚NA). Anal. Calcd. (%) for C29H23ClN8O5: C, 58.15;
H, 3.87; N, 18.71. Found: C, 58.22; H, 3.95; N, 18.86.
2.2.5.2.9. 4-(2-(4-Chlorobenzylidenamino)-6-(2-nitrophen-
yl)pyrimidin-4-yl)-3-methyl-1-(2,4-dinitrophenylphenyl)-1H-
pyrazol-5(4H)-one (6i). mp 205 C; yield 80%; FTIR
(ATR) cm1: 3359 (NH), 2910 (CH3 stretch), 1658 (C‚O ke-
tone), 1367 (CH3 bend), 1526, 1337 (NO2), 1230 (CAN); mass:
m/z 600 (M+), 601 (M+ 1, 32.1%), 602 (M+ 2, 32.7%); 1H
NMR (400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 7.10–
7.20 (m, 4H, ArH), 7.45–7.50 (m, 4H, ArH), 7.55 (d, 2H,
ArH), 7.65 (s, 1H, ArH), 7.90 (s, 1H, NH), 8.15 (s, 1H, ArH),
8.25 (s, 1H, ACH‚NA). Anal. Calcd. (%) for C27H17ClN8O7:
C, 53.96; H, 2.85; N, 18.65. Found: C, 53.56; H, 2.45; N, 18.78.
2.2.5.2.10. 4-(2-(4-Methylbenzylidenamino)-6-(4-chloro-
phenyl)pyrimidin-4-yl)-3-methyl-1-(2,4-dinitrophenylphenyl)-
1H-pyrazol-5(4H)-one (6j). mp 155 C; yield 77%; FTIR
(ATR) cm1: 3354 (NH), 2904 (CH3 stretch), 1657 (C‚O ke-
tone), 1369 (CH3 bend), 1519, 1334 (NO2), 724 (Cl); mass: m/z
569 (M+), 570 (M+ 1, 32.4%), 571 (M+ 2, 32.5%); 1H
NMR (400 MHz, DMSO-d6, d ppm), 2.20 (s, 3H, CH3), 2.40
(s, 3H, CH3), 7.10–7.20 (m, 4H, ArH), 7.45–7.50 (m, 4H,
ArH), 7.50 (d, 2H, ArH), 7.55 (s, 1H, ArH), 7.90 (s, 1H,
NH), 8.10 (s, 1H, ArH), 8.25 (s, 1H,ACH‚NA). Anal. Calcd.
(%) for C27H17N8O7: C, 53.96; H, 2.85; N, 18.65. Found: C,
53.78; H, 2.93; N, 18.57.
2.3. Pharmacological evaluation
2.3.1. Animals
Swiss albino mice of either sex weighing 25–30 g and Wistar
rats weighing in the range 12–140 g were obtained from, Sri
Raghavendra Enterprises (Lab. animals enlist under CPC-
SEA), Bangalore, India. All the animals were housed under
standard ambient conditions of temperature (25 ± 2 C) and
relative humidity of 50 ± 5%. A 12:12 h light:dark cycle was
maintained. All the animals were allowed to have free access
to water and standard palletized laboratory animal diet 24 h
prior to pharmacological studies. All the experimental proce-dures and protocols used in this study were reviewed and ap-
proved by the Institutional Animal Ethical Committee
(IAEC) of ABMRCP, Bangalore, constituted in accordance
with the guidelines of the Committee for the Purpose of Con-
trol and Supervision of Experiments on Animals (CPCSEA),
Government of India.
2.3.2. Preparation of test compounds
After suspending the test compounds in 1.0% aqueous solution
of gum acacia, test samples were administered to test animals
orally. The ﬁrst group was treated with 0.1 mL of 1% gum aca-
cia suspension orally (control), the second group was adminis-
tered with a dose of 50 mg/kg of the suspension of Diclofenac
sodium and Indomethacin (standard). The third group was
treated with 50 mg/kg of the suspension of test compounds.
2.3.3. Anti-inﬂammatory activity
Anti-inﬂammatory activity of the synthesized compounds were
evaluated by carrageenan induced rat paw edema model, at
equimolar doses, using groups of six animals each, to that of
50 mg/kg p.o. of Indomethacin (Menozzi et al., 2003; Winter
et al., 1962). A freshly prepared aqueous suspension of carra-
geenan (1.0% w/v, 0.1 mL) was injected in the subplanter re-
gion of right hind paw of each rat. One group was kept as
control and the animals of the other group were pretreated
with the test drugs, 1 h before the carrageenan treatment.
The volume was measured before and after the carrageenan
treatment at 30 min. interval with the help of plethysmometer.
2.3.4. Analgesic activity
The compounds (5a–5j) exhibited an important analgesic pro-
ﬁle measured by the Eddy’s hot plate method (Eddy and Leim-
bach, 1953; Mathew et al., 2007). Animals were individually
placed on a hot plate maintained at a constant temperature
(55 C) and the reaction of animals, such as paw licking or
jump response (whichever appears ﬁrst) was taken as the end
point. A cut-off time of 15 s was taken as maximum analgesic
response to avoid injury to the paws. The reference group was
administered with a dose of 50 mg/kg of the suspension of Dic-
lofenac sodium (standard). The reaction time for each animal
was noted on the hot plate at 15, 30, 60 and 90 min after the
drug administration. A cut-off period of 15 s was kept to avoid
the injury to the paws of mice.
2.3.5. Antipyretic activity
The antipyretic activity of the test compounds on the feverish
body temperature was determined following a reported proce-
dure (Manna et al., 1992; El-Hawash et al., 2006). Groups of
six fasted rats (24 h) were injected subcutaneously with
brewer’s yeast in physiological saline at a dose of 150 mg/kg
of body weight. After 17 h the initial body temperature was
measured and the test compounds were administered orally
at a dose of 50 mg/kg body weight. The body temperature
was recorded after 1, 3 and 5 h from the administration of
the test compound. The activity was reported in (Table 3)
and Indomethacin was used as a reference drug (5 mg/kg).
2.3.6. Statistical analyses
Data obtained for anti-inﬂammatory, analgesic and antipyretic
activity analyzed by one-way ANOVA followed by Dunnett’s
‘t’ test. Level of signiﬁcance was set to P< 0.05. All statistical
Table 1 Results of anti-inﬂammatory activity of compounds (5a–5j) against carrageenan induced rat paw edema model in rats.
Compounds Mean volume in (mL) after drug treatment (mean ± SEM) Anti-inﬂammatory activity (% inhibition)
1 h 2 h 3 h 1 h 2 h 3 h
Control 1.525 ± 0.015 1.815 ± 0.022 1.95 ± 0.009 – – –
Indomethacin 0.875 ± 0.020 0.806 ± 0.007 0.718 ± 0.014 42.62** 55.59** 63.17**
5a 0.915 ± 0.020 0.826 ± 0.016 0.756 ± 0.011 40** 54.49** 61.23**
5b 1.325 ± 0.130 1.765 ± 0.019 1.518 ± 0.0154 13.11ns 2.75ns 22.15**
5c 0.93 ± 0.264 0.846 ± 0.031 0.76 ± 0.024 39.01** 53.38** 61.02**
5d 0.924 ± 0.013 0.801 ± 0.042 0.744 ± 0.030 39.40* 55.86ns 61.84ns
5e 0.903 ± 0.016 0.846 ± 0.018 0.741 ± 0.033 40.78** 53.38** 62**
5f 0.891 ± 0.021 0.836 ± 0.013 0.731 ± 0.027 41.57** 53.93** 62.51**
5g 1.29 ± 0.091 1.556 ± 0.176 1.793 ± 0.047 15.40ns 14.26ns 8.05ns
5h 0.921 ± 0.013 0.808 ± 0.042 0.74 ± 0.030 39.60** 55.48** 62.05**
5i 1.351 ± 0.146 1.586 ± 0.137 1.803 ± 0.047 11.40ns 12.61 ns 7.53ns
5j 1.493 ± 0.021 1.798 ± 0.058 1.926 ± 0.030 2.09 ns 0.93 ns 1.23ns
Data analyzed by one-way ANOVA followed by Dunnett’s test (n= 6).
* P< 0.05 signiﬁcant from control; ns, not signiﬁcant.
** P< 0.01 signiﬁcant from control; ns, not signiﬁcant.
Figure 1 Pictorial representation of (% inhibition) of anti-inﬂammatory activity.
Table 2 Results of analgesic activity of compounds (5a–5j).
Compounds Reaction time (S) after drug administration (mean ± SEM) Percent increase in reaction time
30 min 60 min 90 min 30 min 60 min 90 min
Control 4.21 ± 0.042 4.23 ± 0.050 4.37 ± 0.01 – – –
Diclofenac sodium 6.23 ± 0.016 7.22 ± 0.004 8.5 ± 0.005 18.72* 27.26* 38.85*
5a 6.03 ± 0.029 7.28 ± 0.126 8.39 ± 0.063 16.86* 28.31* 37.81*
5b 4.96 ± 0.089 5.59 ± 0.134 6.55 ± 00.127 6.95* 12.62* 20.50*
5c 5.8 ± 0.165 6.99 ± 0.110 8.19 ± 0.073 14.73* 25.62* 35.93*
5d 5.83 ± 0.050 6.89 ± 0.121 8.12 ± 0.243 15.01* 24.00* 36.11*
5e 6.16 ± 0.017 7.18 ± 0.014 8.46 ± 0.019 18.07* 27.39* 38.47*
5f 6.05 ± 0.028 7.05 ± 0.029 8.31 ± 0.059 17.05* 26.18* 37.06*
5g 5.51 ± 0.024 7.21 ± 0.119 7.75 ± 0.008 12.04* 27.66* 26.15*
5h 6.09 ± 0.013 7.09 ± 0.015 8.38 ± 0.033 17.42* 26.55* 37.72*
5i 5.00 ± 0.091 5.68 ± 0.244 6.16 ± 0.009 7.32* 13.46* 16.83*
5j 4.53 ± 0.043 5.37 ± 0.173 6.025 ± 0.018 2.96* 10.58* 15.52*
Data analyzed by one-way ANOVA followed by Dunnett’s test (n= 6).
* P< 0.01 signiﬁcant from control.
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Figure 2 Pictorial representation of percent increase in reaction time for analgesic activity.
Table 3 Results of antipyretic activity of compounds (5a–5j).
Compounds Body temperature ± S.E.
0 1 h 2 h 4 h
Control 38.21 ± 0.026 38.19 ± 0.007 38.18 ± 0.004 38.19 ± 0.003
Indomethacin 38.16 ± 0.007 37.47 ± 0.017 36.94 ± 0.009 36.41 ± 0.006
5a 37.89 ± 0.039 37.31 ± 0.064 36.96 ± 0.017 36.39 ± 0.0017
5b 38.1 ± 0.035 37.70 ± 0.024 37.32 ± 0.012 36.64 ± 0.033
5c 38.24 ± 0.038 37.72 ± 0.007 37.18 ± 0.024 36.56 ± 0.035
5d 37.89 ± 0.077 37.53 ± 0.011 37.28 ± 0.009 36.82 ± 0.021
5e 38.18 ± 0.021 37.60 ± 0.011 37.11 ± 0.015 36.55 ± 0.012
5f 38.23 ± 0.163 37.66 ± 0.033 37.17 ± 0.005 36.51 ± 0.02
5g 38.16 ± 0.010 37.76 ± 0.016 37.38 ± 0.012 36.78 ± 0.018
5h 38.26 ± 0.044 37.52 ± 0.069 37.13 ± 0.013 36.53 ± 0.005
5i 38.18 ± 0.013 37.74 ± 0.014 37.35 ± 0.016 36.80 ± 0.02
5j 38.27 ± 0.078 37.93 ± 0.011 37.48 ± 0.014 36.93 ± 0.026
Microwave assisted synthesis of novel pyrazolone derivatives attached to a pyrimidine moiety 241calculations were performed using the evaluation version of
GraphPad InStat 3 (USA) statistical software.
3. Result and discussion
Compounds (5a–5j) reacted with different substituted aromatic
aldehydes in microwave oven to give corresponding Schiff
bases (6a–6j) in very good yields. Various 4-(2-amino-6-
(substituted)pyrimidin-4-yl)-3-methyl-1-(substituted)-1H-pyra-
zol-5(4H)-one (5a–5j) derivatives were synthesized and
screened for anti-inﬂammatory, analgesic and antipyretic
activities. The compounds 5a, 5c–5f, 5h exhibited anti-inﬂam-
matory activity similar to the standard Table 1, (Fig. 1). The
analgesic effects of compound 5e (38.47%) were found to be
nearly similar to than that of Diclofenac sodium (38.85%) Ta-
ble 2, (Fig. 2). The antipyretic activity of the test compounds
are reported in Table 3.
Itwas interesting tonote that out of ten compounds 5a, 5c–5f,
5hwere found to have anti-inﬂammatory, analgesic and antipy-
retic activities near to the standard. The pharmacological studies
suggested that the presence of 4-hydroxy, 4-methoxy, 4-(dimeth-ylamino) and 2-hydroxy as electron releasing groups on phenyl
ring at C6 of amino pyrimidine exhibit anti-inﬂammatory, anal-
gesic and antipyretic activities nearly to the standard. 4-chloro,
3-nitro, 2-nitro, and 4-nitro as electron releasing groups on same
phenyl ring of C6 amino pyrimidine were found to have
decreased activity. From the detailed analysis of the results in
present studies, we conclude that synthesized compounds have
anti-inﬂammatory, analgesic and antipyretic activities due to
the presence of pyrazolone and amino pyrimidine as basic rings.
In view of these observations, we conclude that this series (5a–5j)
could be developed as a novel class of NSAIDs. However, fur-
ther detailed pharmacological screening is required to identify
the potent molecule without severe side effects.
4. Conclusion
Various 4-(2-amino-6-(substituted)pyrimidin-4-yl)-3-methyl-1-
(substituted)-1H-pyrazol-5(4H)-one (5a–5j) derivatives were
synthesized and screened for anti-inﬂammatory, analgesic and
antipyretic activities. Compounds (5a–5j) reacted with different
substituted aromatic aldehydes inmicrowave oven to give corre-
242 R.V. Antre et al.sponding Schiff bases (6a–6j) in very good yields. It was interest-
ing to note that out of ten compounds 5a, 5c–5f, 5h were found
to have anti-inﬂammatory, analgesic and antipyretic activities
near to the standard. The pharmacological studies suggested
that the presence of 4-hydroxy, 4-methoxy, 4-(dimethylamino)
and 2-hydroxy as electron releasing groups on phenyl ring at
C6 of amino pyrimidine exhibits anti-inﬂammatory, analgesic
and antipyretic activities nearly to the standard. 4-chloro,
3-nitro, 2-nitro, and 4-nitro as electron releasing groups on the
same phenyl ring of C6 amino pyrimidine were found to have de-
creased activity. From detailed analysis of the results in present
studies, we conclude that synthesized compounds have anti-
inﬂammatory, analgesic and antipyretic activities due to the
presence of pyrazolone and amino pyrimidine as basic rings.
In view of these observations, we conclude that this series (5a–
5j) could be developed as a novel class of NSAIDs. However,
further detailed pharmacological screening is required to iden-
tify the potent molecule without severe side effects.Acknowledgments
The authors gratefully acknowledge the IISc. Bangalore and
University of Hyderabad (School of Chemistry) for the spec-
tral analysis. Also we are thankful to the Department of
Medicinal Chemistry, and Department of Pharmacology, Ach-
arya and B.M. Reddy College of Pharmacy, Bangalore for
providing constant support during research work.
References
Bhandari, S.V., Dangre, S.C., Bothara, K.G., Patil, A.A., Sarkate,
A.P., Lokwani, D.K., 2009. Design, synthesis and pharmacological
screening of novel nitric oxide donors containing 1,5-diarylpyraz-
olin-3-one as nontoxic NSAIDs. Eur. J. Med. Chem. 44, 4622–
4636.
Bondock, S., Rabie, R., Etman, H.A., Fadda, A.A., 2008. Synthesis
and antimicrobial activity of some new heterocycles incorporating
antipyrine moiety. Eur. J. Med. Chem. 43, 2122–2129.
Brana, M.F., Gradillas, A., Ovalles, A.G., Lopez, B., Acero, N.,
Llinares, F., Mingarro, D.M., 2006. Synthesis and biological
activity of N,N-dialkylaminoalkyl substituted bisindolyl and
diphenyl pyrazolone derivatives. Bioorg. Med. Chem. 14, 9–16.
Chao, E.Y., Caravella, J.A., Watson, M.A., Campobasso, N., Ghis-
letti, S., Billin, A.N., 2008. Structure guided design of N-phenyl
tertiary amines as transrepression selective liver X receptror
modulators with anti-inﬂammatory activity. J. Med. Chem. 51,
5758–5765.
Cheeseright, T.J., Holm, M., Lehmann, F., Luik, S., Gottert, M.,
Melville, J.L., Laufer, S., 2009. Novel lead structures for p38 MAP
kinase via ﬁeld screen virtual screening. J. Med. Chem. 52, 4200–
4209.
Chegaev, K., Cena, C., Giorgis, M., Rolando, B., Tosco, P.,
Bertinaria, M., 2009. Edaravone derivatives containing NO-donor
functions. J. Med. Chem. 52, 574–578.
Eddy, N.B., Leimbach, D.J., 1953. Synthetic analgesics II. Dithie-
nylbutenyl and dithienylbutylamines. J. Pharmacol. Exp. Ther.,
385–393.
El-Hawash, A.M., El-Sayed, A.M.B., El-Ashmawey, I.M., 2006.
Nonsteroidal antiinﬂammatory agents-part-2 antiinﬂammatory,
analgesic and antipyretic activity of some substituted 3-pyrazolin-
5-ones and 1,2,4,5,6,7-3H-hexahydroindazol-3-ones. Eur. J. Med.
Chem. 41, 155–165.Filho, V.C., Correa, R., Vaz, Z., Calixto, J.B., Nunes, R.J., Pinheiro,
T.R., Andricopulo, A.D., Yunes, R.A., 1998. Further studies on
analgesic activity of cyclic imides. Farmaco 53, 55–57.
Gokce, M., Utku, S., Kupeli, E., 2009. Synthesis and analgesic and
anti-inﬂammatory activities 6-substituted-3(2H)-pyridazinone-2-
acetyl-2-(p-substituted/nonsubstituted benzal) hydrazone deriva-
tives. Eur. J. Med. Chem. 44, 3760–3764.
Higashi, Y., Jitsuikia, D.D., Chayamab, K., Yoshizumia, M., 2006.
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free
radical scavenger, for treatment of cardiovascular diseases. Recent
Pat. Cardiovasc. Drug Discovery 1, 85–93.
Hynes, J.J., Dyckman, A.J., Lin, S., Wrobleski, S.T., Hong, W.,
Gillooly, K.M., 2008. Design, synthesis, and anti-inﬂammatory
properties of orally active 4-(phenylamino)-pyrrole[2,1-f][1,2,4]tri-
azine P38a mitogen activated protein kinase inhibitors. J. Med.
Chem. 41, 4–16.
Ismail, M.M.F., Ammar, Y.A., El-Zahaby, H.S.A., Eisa, S.I., Barakat,
S.E., 2007. Synthesis of novel 1-pyrazolylpyridin-2-ones as
potential anti-inﬂammatory and analgesic agents. Arch. Pharm.
Life Sci. 340, 476–482.
Jensen, B.S., 1959. The synthesis of 1-phenyl-3-methyl-4-acyl-pyrazo-
lones-5. Acta Chim. Scand. 13, 1668–1670.
Kalgutkar, A.S., Zhao, Z., 2001. Discovery and design of selective
cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inﬂammatory
drugs with potential utility as anti-cancer agents. Curr. Drug
Targets 2, 79–106.
Kawai, H., Nakai, H., Suga, M., Yuki, S., Watanabe, T., Saito, K.I.,
1997. Effects of a novel free radical scavenger, MCl-186, on
ischemic brain damage in the rat distal middle cerebral artery
occlusion model. J. Pharmacol. Exp. Ther. 281, 921–927.
Kim, K.R., Ju-Lee, K., Ji-Sun, K., Zaesung, N., Hyoung, R.K., Hyae,
G.C., 2005. EK-6136 (3-methyl-4-(O-methyl-oximino)-1-phenylpy-
razolin-5-one): a novel Cdc25B inhibitor with antiproliferative
activity. Eur. J. Pharmacol. 528, 37–42.
Kimata, A., Nakagawa, H., Ohyama, R., Fukuuchi, T., Ohta, S.,
Suzuki, T., Miyata, N., 2007. New series of antiprion compounds:
pyrazolone derivatives have the potent activity of inhibiting
protease-resistant prion protein accumulation. J. Med. Chem. 50,
5053–5056.
Manna, F., Chimenti, F., Bolasco, A., 1992. Anti-inﬂammatory,
analgesic and antipyretic N-acetyl-D2-pyrazolines and dihydrothi-
enocoumarines. Eur. J. Med. Chem. 27, 633–639.
Manojkumar, P., Ravi, T.K., Gopalakrishnan, S., 2009. Antioxidant
and antibacterial studies of arylazopyrazoles and aryl-
hydrazonopyrazolones containing coumarin moiety. Eur. J. Med.
Chem. 44, 4690–4694.
Mathew, V., Keshavayya, J., Vaidya, V.P., Giles, D., 2007. Studies on
synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues. Eur.
J. Med. Chem. 42, 823–840.
Menozzi, G., Merello, L., Fossa, P., 2003. 4-Substituted 1,5-diarylpy-
razole, analogues of celecoxib: synthesis and preliminary evaluation
of biological properties. Farmaco 58, 795–808.
Mohanty, S.K., Shridhar, R., Padmanavan, S.Y., Rao, S., Mittra,
A.S., 1977. Fungicidal activity and synthesis of 5-thiopyrazolones
and compounds having a-pyrone attached to pyrazolin nucleus.
Ind. J. Chem. 15 (B), 1146–1148.
O’Neill, L.A., 2006. Targeting signal transduction as a strategy to treat
inﬂammatory diseases. Nat. Rev. Drug Discovery 5, 549–563.
Pal, S., Mareddy, J., Devi, N.S., 2008. High speed synthesis of
pyrazolone using microwave-assisted neat reaction technology. J.
Braz. Chem. Soc. 19, 1207–1214.
Pasinetti, G.M., 1998. Cyclooxygenase and inﬂammation in Alzhei-
mer’s disease: experimental approaches and clinical interventions.
J. Neurosci. Res. 54, 1–6.
Ragavan,R.V.,Vijayakumar,V.,Kumari,N.S., 2009. Synthesis of some
novel bioactive 4-oxy/thio substituted-1 H-pyrazol-5(4H)-ones via
Microwave assisted synthesis of novel pyrazolone derivatives attached to a pyrimidine moiety 243efﬁcient cross-claisen condensation. Eur. J. Med. Chem. 44, 3852–
3857.
Raman, N., Kulandaisamy, A., Jeyasubramanian, K., 2002. Synthesis,
spectral, redox, and antimicrobial activity of schiff base transition
metal (II) complexes derived from 4-aminoantipyrine and benzil.
Synth. React. Inorg. Met. 32, 1583–1610.
Raman, N., Kulandaisamy, A., Jeyasubramanian, K., 2005. Synthesis,
structural characterization, redox, and antibacterial studies of 12-
membered tetraaza macrocyclic Cu(II), Ni(II), Co(II), Zn(II), and
VO(IV) complexes derived from 1,2-(diimino-40-antipyrinyl)-1,2-
diphenylethane and O-phenylenediamine. Synth. React. Inorg.
Met. 34, 17–43.
Souza, F.R., Souza, V.T., Ratzlaff, V., Borges, L.P., Oliveira, M.R.,
Bonacorso, H.G., 2002. Hypothermic and antipyretic effects of 3-
methyl- and 3-phenyl-5-hydroxy-5-trichloromethyl-4,5-dihydro-1H-pyrazole-1-carboxyamides in mice. Eur. J. Pharmacol. 451,
141–147.
Stefan, A.L., Hauser, D.R.J., Domeyer, D.M., Katrin, K., Liedtke,
A.J., 2008. Design, synthesis, and biological evaluation of novel tri-
and tetra-substituted imidazoles as highly potent and speciﬁc ATP-
mimetic inhibitors of p38 MAP kinase: focus on optimized
interactions with the enzyme’s surface-exposed front region. J.
Med. Chem. 51, 4122–4129.
Watanabe, T., Yuki, S., Egawa, M., Nishi, H., 1994. Protective effects
of MCI-186 on cerebral ischemia: possible involvement of free
radical scavenging and antioxidant actions. J. Pharmacol. Exp.
Ther. 268, 1597–1604.
Winter, C.A., Risley, E.A., Nuss, G.N., 1962. Carrageenan-induced
edema in hind paw of rat as a assay for anti-inﬂammatory drugs.
Proc. Soc. Exp. Biol. 111, 544–547.
